Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Immunoglobulin Light-chain Amyloidosis 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Plasma Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

trifluridine tipiracil drug combination 1spartalizumab 1selinexor 1ixazomib 1futibatinib 1fludarabine 1atezolizumab 1TAS-116 1Ramucirumab 1Ifosfamide 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Alveolar Soft Part × ixazomib × Clear all
NCT03880123 2020-11-27

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Columbia University

Phase 1 Withdrawn
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡